Early Treatment of NOD Mice With B7-H4 Reduces the Incidence of Autoimmune Diabetes

OBJECTIVE Autoimmune diabetes is a T cell–mediated disease in which insulin-producing β-cells are destroyed. Autoreactive T cells play a central role in mediating β-cell destruction. B7-H4 is a negative cosignaling molecule that downregulates T-cell responses. In this study, we aim to determine the role of B7-H4 on regulation of β-cell–specific autoimmune responses. RESEARCH DESIGN AND METHODS Prediabetic (aged 3 weeks) female NOD mice (group 1, n = 21) were treated with intraperitoneal injections of B7-H4.Ig at 7.5 mg/kg, with the same amount of mouse IgG (group 2, n = 24), or with no protein injections (group 3, n = 24), every 3 days for 12 weeks. RESULTS B7-H4.Ig reduced the incidence of autoimmune diabetes, compared with the control groups (diabetic mice 28.6% of group 1, 66.7% of group 2 [P = 0.0081], and 70.8% of group 3 [group 1 vs. 3, P = 0.0035]). Histological analysis revealed that B7-H4 treatment did not block islet infiltration but rather suppressed further infiltrates after 9 weeks of treatment (group 1 vs. 2, P = 0.0003). B7-H4 treatment also reduced T-cell proliferation in response to GAD65 stimulation ex vivo. The reduction of diabetes is not due to inhibition of activated T cells in the periphery but rather to a transient increase of Foxp3+ CD4+ T-cell population at one week posttreatment (12.88 ± 1.29 vs. 11.58 ± 1.46%; n = 8; P = 0.03). CONCLUSIONS Our data demonstrate the protective role of B7-H4 in the development of autoimmune diabetes, suggesting a potential means of preventing type 1 diabetes by targeting the B7-H4 pathway.

[1]  J. Bluestone,et al.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.

[2]  J. Stockman.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2010 .

[3]  P. Xiong,et al.  B7-H4 transfection prolongs beta-cell graft survival. , 2009, Transplant immunology.

[4]  Dorothy N. Kakoola,et al.  Faculty Opinions recommendation of Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. , 2009 .

[5]  Lieping Chen,et al.  Local Expression of B7-H4 by Recombinant Adenovirus Transduction in Mouse Islets Prolongs Allograft Survival , 2009, Transplantation.

[6]  C. Benoist,et al.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.

[7]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[8]  L. Wen,et al.  ICOS Mediates the Development of Insulin-Dependent Diabetes Mellitus in Nonobese Diabetic Mice1 , 2008, The Journal of Immunology.

[9]  F. Vincenti.  Costimulation blockade in autoimmunity and transplantation. , 2008, The Journal of allergy and clinical immunology.

[10]  M. Jordana,et al.  Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice , 2006, Molecular and Cellular Biology.

[11]  Lieping Chen,et al.  Suppression of Human T-Cell Responses to β-Cells by Activation of B7-H4 Pathway , 2006, Cell transplantation.

[12]  Lieping Chen,et al.  Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway. , 2006, Cell transplantation.

[13]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[14]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[15]  Mark S. Anderson,et al.  The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.

[16]  G. Freeman,et al.  CD4 CD25 T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion , 2004 .

[17]  N. Sarvetnick,et al.  The pathogenesis of diabetes in the NOD mouse. , 2004, Advances in immunology.

[18]  R. Nurieva,et al.  Regulation of immune and autoimmune responses by ICOS. , 2003, Journal of Autoimmunity.

[19]  L. Adorini,et al.  Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development , 2003, The Journal of Immunology.

[20]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[21]  P. Loke,et al.  B7x: A widely expressed B7 family member that inhibits T cell activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[23]  C. Dong,et al.  B7S1, a novel B7 family member that negatively regulates T cell activation. , 2003, Immunity.

[24]  G. Zhu,et al.  B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. , 2003, Immunity.

[25]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[26]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[27]  J. Killestein.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[28]  F. Lepault,et al.  Pancreatic Lymph Nodes Are Required for Priming of β Cell Reactive T Cells in NOD Mice , 2002, The Journal of experimental medicine.

[29]  R. Noelle,et al.  Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. , 2002, Blood.

[30]  Mary Collins,et al.  The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. , 2002, Annual review of immunology.

[31]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.

[32]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[33]  C. Benoist,et al.  Initiation of Autoimmune Diabetes by Developmentally Regulated Presentation of Islet Cell Antigens in the Pancreatic Lymph Nodes , 1999, The Journal of experimental medicine.

[34]  A. Abbas,et al.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.

[35]  C. Benoist,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes , 1998, The Journal of experimental medicine.

[36]  R. Tisch,et al.  CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. , 1997, Journal of immunology.

[37]  P. Linsley,et al.  CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics , 1997, The Journal of experimental medicine.

[38]  S. Sakaguchi,et al.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation , 1996, The Journal of experimental medicine.

[39]  R. Tisch,et al.  Insulin-Dependent Diabetes Mellitus , 1996, Cell.

[40]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[41]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[42]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[43]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[44]  H. Drexhage,et al.  Immunohistochemical Characterization of Monocytes-Macrophages and Dendritic Cells Involved in the Initiation of the Insulitis and β-Cell Destruction in NOD Mice , 1994, Diabetes.

[45]  E. Leiter,et al.  Adoptive Transfer of Diabetes Into Immunodeficient NOD-scid/scid Mice: Relative Contributions of CD4+ and CD8+ T-Cells From Diabetic Versus Prediabetic NOD.NON-Thy-1a Donors , 1993, Diabetes.

[46]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[47]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[48]  A. Hayward,et al.  Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. , 1989, Journal of immunology.

[49]  M. Sharf,et al.  Fetal obstructive uropathy [corrected]. , 1988, Lancet.

[50]  Th. Mandel,et al.  Progression From Insulitis to β-Cell Destruction in NOD Mouse Requires L3T4+ T-Lymphocytes , 1988, Diabetes.

[51]  C. Fathman,et al.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. , 1988, Science.

[52]  T. Hanafusa,et al.  Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. , 1985, Clinical and experimental immunology.

[53]  D. Steinmuller.  Adoptive transfer. , 1984, Methods in enzymology.

[54]  J. McNally,et al.  EVIDENCE FOR A LONG PREDIABETIC PERIOD IN TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUS , 1981, The Lancet.